INDIANAPOLIS, Ind., December 20, 2007 — BioCrossroads announces that William R. Ringo Jr. has been elected as a member of our Board of Directors. Ringo retired from Eli Lilly and Company in 2001 after a 28-year tenure of service in a variety of key roles; his last position was President of Oncology and Critical Care

Products. Since 2001, Ringo has served in a variety of board and leadership positions in the biotechnology sector, including as President and Chief Executive Officer of Abgenix, Inc.(later acquired by Amgen) and as Interim President and CEO of InterMune. Ringo is currently the CEO in Residence at Warburg Pincus, a private equity firm, and the Executive in Residence at Sofinnova Ventures.

“As BioCrossroads continues to build strategic relationships and collaborative ventures outside the state that will benefit Indiana companies and workforce, Bill’s vast experience is a natural fit,” said Dr. August Watanabe, Chairman of the Board of BioCrossroads. “He still has roots in Indiana, and he’ll be a great resource as we further develop our connections within the other centers of America’s life sciences industry.”

Ringo currently serves as chairman of the board of directors for Hyperion, InterMune, Inc., and Portola Pharmaceuticals; he is a member of the board of directors of Allos Therapeutics, Inspire Pharmaceuticals, Inc. and Alvine Pharmaceuticals.

About BioCrossroads

BioCrossroads ( is Indiana’s initiative to grow the life sciences, a public-private collaboration that supports the region’s research and corporate strengths while encouraging new business development. BioCrossroads provides money and support to life sciences businesses, launches new life sciences businesses, expands collaboration and partnerships among Indiana’s life science institutions, expands science education and markets Indiana’s life sciences industry.